$-0.92
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
0
P/B Ratio
15.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-5.8 %
ROCE
-- %
Industry P/E
24.41
EV/EBITDA
2.4
Debt to Equity
0
Book Value
$--
EPS
$2
Face value
--
Shares outstanding
581,000
CFO
$-247.05 Mln
EBITDA
$-300.14 Mln
Net Profit
$-308.32 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
| -98.9 | -- | -91.6 | -99.0 | -93.2 | -78.7 | -73.7 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
| -93.2 | -58.3 | 3.2 | 17.9 | -76.7 | -89.4 | 41.5 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.3 | 0.2 | 2.0 | 4.1 | -1,480.7 | -- | 0 | 15.1 |
| 12.5 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 40.9 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 186.0 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 73.3 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 13.7 | 11,337.9 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.6 | 2.8 | |
| 22.8 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 5,499.1 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.7 | 1.1 | |
| 231.3 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an... intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Read more
Founder, Chairman, CEO & President
Dr. Raj Mehra J.D., Ph.D.
Founder, Chairman, CEO & President
Dr. Raj Mehra J.D., Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Seelos Therapeutics Inc (SEEL) is $0.25 (NASDAQ) as of 17-Dec-2024 09:30 EDT. Seelos Therapeutics Inc (SEEL) has given a return of -93.16% in the last 3 years.
Since, TTM earnings of Seelos Therapeutics Inc (SEEL) is negative, P/E ratio is not available.
The P/B ratio of Seelos Therapeutics Inc (SEEL) is 15.10 times as on 17-Dec-2024, a 170 premium to its peers’ median range of 5.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-0.36
|
-0.41
|
|
2022
|
-0.03
|
-0.23
|
|
2021
|
-0.08
|
0.10
|
|
2020
|
-0.15
|
1.10
|
|
2019
|
-0.02
|
-172.52
|
The 52-week high and low of Seelos Therapeutics Inc (SEEL) are Rs -- and Rs -- as of 27-Apr-2026.
Seelos Therapeutics Inc (SEEL) has a market capitalisation of $ 0 Mln as on 17-Dec-2024. As per SEBI classification, it is a company.
Before investing in Seelos Therapeutics Inc (SEEL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.